 |
|
Generic Substitution and Optimal Patient Care
Arch Intern Med. 1999;159:429-433.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
IT WOULD BE HARD to find anyone who disagrees that all health care practitioners should be concerned with the efficacy, safety, and cost of treatments provided to their patients. Most would also agree that the first 2 considerations should usually outweigh the third. However, today's climate in health care often seems to be focused increasingly on cost as the primary driver of care. As the economics become increasingly visible to the public and payers, the producers and consumers of health care often find themselves on opposing sides of positions related to fundings. Therefore, it is ever important that information used to make decisions related to the financing of care be unbiased and as easy as possible to understand. This ideal does not always occur. One area where passion and promotion rather than evidence are increasingly influencing decisions relates to the substitution of Food and Drug Administration (FDA)–approved generic equivalents for . . . [Full Text of this Article]BANAHAN AND KOLASSA'S STUDY AND ITS IMPACT
PROBLEMS WITH GENERIC SWITCHING
ISSUES SURROUNDING SUBSTITUTION
COMMENT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-analysis
Kesselheim et al.
JAMA 2008;300:2514-2526.
ABSTRACT
| FULL TEXT
Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000
Haas et al.
ANN INTERN MED 2005;142:891-897.
ABSTRACT
| FULL TEXT
|
